2:41 AM
Login form
Entries archive

My site

Main » 2016 » December » 08

Revolutionary Action Sports Competition Returns to Salt Lake City’s Rice-Eccles Stadium June 24, 2017 

Tickets On Sale Friday, December 9


LOS ANGELES - Tuesday, December 6th 2016 [ME NewsWire]
(BUSINESS WIRE)-- After making headlines in its 2016 debut with electrifying feats and an unprecedented amount of world firsts, Nitro World Games will raise the bar even higher next year. Created by action sports icon Travis Pastrana with Nitro Circus CEO and Creative Director Mike Porra, Nitro World Games returns to Salt Lake City, Utah U.S.A. on Saturday, June 24 when Rice-Eccles Stadium hosts an adrenaline-fueled competition to see who will be crowned world champion in action sports’ most exciting disciplines: FMX, BMX, Skate, Inline and Scooter. NBC will televise the action-packed finals in primetime in the U.S.
Tickets to the June 24 Nitro World Games go on sale Friday, December 9 at 10:00 A.M. (Mountain time, U.S.A.) at n ... Read more »

Views: 198 | Added by: uaeonlinenews | Date: 12.08.2016 | Comments (0)


● Sàvant Data Systems (SDS) collaborates with Aswaaq to integrate game-changing solutions in the UAE’s retail sector known as the solid omni-channel strategy which involves analyzing shopper behaviour, providing shoppers relevant information correctly and promptly, and restructuring the organization to take decisions quickly. :

● SDS will introduce various technology integrated systems including People Counting Platform that enables businesses to make strategic decision on a day-to-day basis to improve sales, monitor, marketing campaigns and control overhead operational costs.

Dubai, United Arab Emirates - Thursday, December 8th 2016 [ME NewsWire]

 Sàvant Data Systems (SDS), a leading retail intelligence provider for UAE’s retail, shopping, banking and commercial sectors, partners with Dubai-based shopping and retail conglomerate Aswaaq to better the retail experience of shoppers in the UAE through intelligent and innovativ ... Read more »

Views: 150 | Added by: africa-live | Date: 12.08.2016 | Comments (0)

TORONTO - Thursday, December 8th 2016 [ME NewsWire]

(BUSINESS WIRE)-- Following the voluntary administration process of Wynyard Group Limited of Auckland, New Zealand, Resolver finalizes the acquisition of Wynyard’s Risk Management suite of products. Resolver has greatly expanded its customer base and global reach with the acquisition of the Wynyard Risk Management (WRM), Kairos Risk Management and Methodware Enterprise Risk Assessor (ERA) applications. Over 150 customers using the WRM products will be provided continual support and long-term product roadmap through Resolver.

Resolver has re-engaged a significant portion of the original WRM team including Bob Adderley, Scott James, Clint Walker and Adam Belfield to provide uninterrupted support of these platforms. “It is our privilege to provide a long-term home for the Wynyard WRM customers and employees,” states Will Anderson, CEO of Resolver Inc.

Continued Product Support and Enhancement< ... Read more »

Views: 228 | Added by: africa-live | Date: 12.08.2016 | Comments (0)

INGELHEIM, Germany & VIENNA - Wednesday, December 7th 2016 [ME NewsWire]

    International survey showed high global EGFR testing rates prior to first-line lung cancer therapy but highlighted a shortfall in the number of test results received before deciding on therapy
    Nearly one in five patients are at risk of missing out on treatments personalised to their specific lung cancer type
    In addition, more than half of all physicians surveyed did not recognise differences between available targeted therapies to treat EGFR mutation-positive lung cancer

(BUSINESS WIRE)-- Results from a new international survey of physicians revealed more patients with advanced non-small cell lung cancer (NSCLC) could benefit from targeted therapy based on their lung cancer type, over the use of chemotherapy. Test results to identify EGFR mutations were not available prior to deciding on therapy for nearly one in five (18%* ... Read more »

Views: 178 | Added by: uaeonlinenews | Date: 12.08.2016

All HD+ satellite households in Germany are now able to receive Eurosport 1HD

LUXEMBOURG - Wednesday, December 7th 2016 [ME NewsWire]

(BUSINESS WIRE)-- SES S.A. (Euronext Paris:SESG) (LuxX:SESG) announced today that MX1, a wholly-owned subsidiary of SES, has signed a multi-year agreement with Discovery Networks Germany, Eurosport’s parent company, to handle technical services and satellite transmission of the Eurosport 1HD channel on HD+, SES’s German HD platform. MX1’s services include encoding, uplink and delivery in HD via an ASTRA satellite at 19.2 degrees East. The Eurosport 1HD channel was added to the HD+ package on 1 December 2016, increasing its encrypted HDTV offering to 23 channels, in addition to 35 free-to-air HD channels.

“We are very pleased to support Discovery Networks Germany in making Eurosport 1HD available for HD+ customers via satellite. Satellite dissemination offers networks such as Discovery a reliable way to r ... Read more »

Views: 197 | Added by: uaeonlinenews | Date: 12.08.2016

Matthieu de Kalbermatten nominated as CEO

MULHOUSE, France - Wednesday, December 7th 2016 [ME NewsWire]

(BUSINESS WIRE)-- CellProthera, which offers the most advanced cell therapy for the regeneration of the damaged heart muscle after myocardial infarction, has changed its corporate governance and appointed Matthieu de Kalbermatten as CEO. He succeeds Jean-Claude Jelsch (currently Chairman of the Supervisory Board) and now manages the bio-tech firm alongside the Chairman, Professor Philippe Hénon.

The change to the governance of CellProthera aims mainly at : driving current and future clinical studies, increasing the company's global presence, and ensuring the successful marketing of the innovative therapy worldwide.

With his solid track record of success within various organizations, Matthieu de Kalbermatten brings along management skills that are strategic for CellProthera’s development. He has demonstrated detailed knowledge of the operat ... Read more »

Views: 181 | Added by: uaeonlinenews | Date: 12.08.2016 | Comments (0)

INGELHEIM, Germany & VIENNA - Wednesday, December 7th 2016 [ME NewsWire]

    Mesothelioma is a rare and difficult-to-treat cancer with no targeted treatment options currently approved
    Oral triple angiokinase inhibitor nintedanib meets primary endpoint of progression-free survival (9.4 vs 5.7 months) and significantly reduced the risk of disease progression by 44% in Phase II study versus standard of care
    Phase III extension trial (LUME-Meso [NCT01907100]) is currently recruiting patients worldwide

(BUSINESS WIRE)-- Boehringer Ingelheim today announced that the LUME-Meso Phase II trial in patients with unresectable malignant pleural mesothelioma (MPM) met its primary endpoint of progression-free survival (PFS). The data presented at the 17th IASLC World Conference on Lung Cancer in Vienna, showed nintedanib* plus pemetrexed/cisplatin demonstrated a meaningful clinical benefit compared to placebo plus ... Read more »

Views: 198 | Added by: uaeonlinenews | Date: 12.08.2016

Hilton Bali Resort Welcomes Guests in the Heart of Nusa Dua

BALI, Indonesia & MCLEAN, Va. - Wednesday, December 7th 2016 [ME NewsWire]

(BUSINESS WIRE)-- Hilton Hotels & Resorts today announced the opening of Hilton Bali Resort, which joins 130 distinguished resort properties across the Hilton (NYSE: HLT) portfolio located in some of the world’s most sought-after destinations. Designed for travelers seeking relaxation and rejuvenation, Hilton Bali Resort brings breathtaking views, extensive recreation facilities and magnificent event space to the Nusa Dua beach enclave on Bali’s southern peninsula.

“Hilton Bali Resort is a significant addition to our flagship brand portfolio, bringing Hilton Hotels & Resorts’ renowned hospitality to one of the world’s premier island destinations,” said Sean Wooden, vice president, brand management, Asia Pacific, Hilton. “Hilton continues to deliver world-class service and p ... Read more »

Views: 167 | Added by: africa-live | Date: 12.08.2016 | Comments (0)

Interim study findings further support safety, efficacy and tolerability in squamous and elderly patients with advanced NSCLC, consistent with results previously seen in the pivotal Phase III trial

BOUDRY, Switzerland - Wednesday, December 7th 2016 [ME NewsWire]

(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced interim results from the ABOUND clinical trial program evaluating the use of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in patients with advanced non-small cell lung cancer (NSCLC). Interim data being presented from the ABOUND trials during the IASLC 17th World Conference on Lung Cancer (WCLC) reinforces the benefit of ABRAXANE/carboplatin doublet therapy in first-line NSCLC.

Interim ABOUND.70+ data in 128 elderly patients (≥ 70 years old) receiving first-line treatment with ABRAXANE/carboplatin for advanced NSCLC found that 91 (73%) patients experienced grade ≥2 peripheral neuro ... Read more »

Views: 192 | Added by: africa-live | Date: 12.08.2016 | Comments (0)